JAMA Network
About The Study: In this case-control study with 164,000 participants, the CoronaVac and Pfizer-BioNTech vaccines were generally estimated to be effective against severe outcomes due to SARS-CoV-2 Omicron infection, but protection among older individuals was more likely to wane six months after the second dose. Hence, a booster dose is recommended for older patients to restore immunity.
Authors: Ka Chun Chong, Ph.D., and Eng Kiong Yeoh, M.B.B.S., of the Chinese University of Hong Kong, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.54777)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
